The Diagnosis: The Silent Cost of Muting Desire
There is a man on Reddit who reports that within three weeks of starting Ozempic, he stopped gambling, drinking, biting his nails, and viewing pornography. He was not intentionally trying to quit any of these behaviors.
His credit card bill dropped by half. He left an unfinished drink at a restaurant for the first time in his adult life. He walked past a casino in Las Vegas and felt nothing. The man who once could not pass a restaurant without calculating how much alcohol he could consume before his wife noticed was now strolling past slot machines as if they were merely decorative plants in a waiting room.
He posted to ask if the medication was broken. It was not. It was working exactly as designed. The issue is that no one—not the manufacturer, the regulators, or the physicians—adequately explained that the "design" might also eliminate the interest in being a person who wants things.
As a licensed therapist for forty years, I have watched patients struggle with the gap between what they want and what they want to want. This medication is truly different. It is not just a temporary fix; it is changing the fundamental nature of the self, and we are only now starting to ask what that means.
The Conflict of Narratives
On social media, two narratives are colliding. One side views the drug as a miracle that silences "food noise"—the constant mental chatter about eating. Users describe a sense of liberation, as if a demanding voice in their head has finally fallen silent.
The second narrative is more somber: the "emotional flatline." These users report an inability to feel pleasure in anything—food, intimacy, hobbies, or even their own families. They describe feeling like observers in their own lives, watching their children through a security camera rather than participating in the joy.
The Dopamine Connection
The truth is that these drugs work in the brain. They influence the reward pathway—specifically dopamine, the chemical linked to motivation and pleasure. By making eating less pleasurable, the drug facilitates weight loss. However, dopamine does not discriminate. It does not know the difference between a craving for a meal and the drive for professional success or the joy of a sunset.
When you turn down the volume on the reward system, you turn it down on everything. You cannot choose which channels go quiet.
A Failure in Clinical Testing
Perhaps the most concerning aspect is the clinical trial process. When the primary manufacturers ran the trials for FDA approval, they excluded patients with psychiatric histories. A drug that fundamentally alters the brain's reward system—the very system that malfunctions in depression, anxiety, and addiction—was tested almost exclusively on people without those conditions.
We have approved a medication that rewires brain chemistry without testing it on those whose chemistry was already struggling. We are now prescribing it to millions, many of whom fall into those excluded categories, and acting surprised by the psychiatric side effects.
The Invention of "Food Noise"
Before these medications, "food noise" was not a recognized clinical term. We have retroactively created a medical concept because patients needed a way to describe what the drug had silenced. But in our rush to celebrate this silence, we have not asked if some of that "noise" served a purpose—like the drive to connect, pursue goals, or feel hope. We have effectively silenced the smoke alarm without checking to see if there is a fire.
The Economic Engine
The financial stakes are staggering. The revenue generated by these drugs is so vast that the manufacturer's market value has at times exceeded the entire economic output of its home country. This does not inherently make the drug dangerous, but it necessitates skepticism regarding research that might impact such a massive bottom line.
The Telehealth Factor
Today, many prescriptions are issued via telehealth platforms in mere minutes. The screening often focuses on BMI and insurance rather than a deep dive into psychiatric history. Furthermore, while the version of the drug marketed for weight loss warns of depression and suicidal thoughts, the version marketed for diabetes—containing the exact same active ingredient—does not always carry the same emphasis.
A Tool or a Surrender?
For some, particularly those battling severe addiction, this dopamine suppression is a lifeline. It provides a "quiet" they have never known. But for those whose systems were functioning normally, it can feel like losing one's essence.
We are currently treating a population the size of a small nation with hope and a needle, but without sufficient long-term data. We may be entering a future where we chemically modify our capacity to want things because we have built a world with too many things to want.
The "Ozempic personality" is a reality. We simply do not yet know the total cost of the invoice.
